P&G's Health Care segment eyes sustained growth as improving cold and cough demand, product innovation and the Thorne acquisition create fresh opportunities.

Procter & Gamble's defensive portfolio and strong cash generation provide a stable foundation, but recent margin compression from input cost inflation and muted volume growth warrant caution.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has been stable at ~1.5% annually, but gross margin contracted 390 basis points from peak to 48.5% in 2026Q4, driving operating margin down to 18.6% from 26.7% a year earlier.
Analysts hold a positive outlook with a consensus rating of 'Buy' and a median price target of $165.00, implying a potential upside of 12.7%.
P&G is executing a multi-category innovation rollout, with early signs of success showing double-digit growth in some product lines.
The company plans to return approximately $15 billion to shareholders in fiscal 2026 through dividends and buybacks.
There are concerns about deepening U.S. consumer softness and increased competition from private labels affecting P&G's pricing power.
Sustained weakness in consumer demand could lead to volume declines, particularly in segments like grooming and fabric/home care.
Higher commodity costs and tariffs are expected to negatively impact margins, with tariffs alone costing around $400 million in fiscal 2026.
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 22, 2026 | $2.00+6.4% vs $1.88 | $23.3B+2.1% vs $22.8B |
Q3 2026 Jul 29, 2026 | $1.43+1.4% vs $1.41 | $21.2B-0.8% vs $21.4B |
Q2 2026 Apr 24, 2026 | $1.59+1.9% vs $1.56 | $21.2B+3.4% vs $20.5B |
Q1 2026 Jan 22, 2026 | $1.88+1.1% vs $1.86 | $22.2B-0.4% vs $22.3B |
P&G's Health Care segment eyes sustained growth as improving cold and cough demand, product innovation and the Thorne acquisition create fresh opportunities.

More than 600 ETFs now bet on a single stock, and one market veteran says the people buying them are losing badly while the sponsors cash in. Why does a simple 10% swing quietly punish traders, and what do two Dividend Kings do differently?
The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) grounds countless retirement portfolios. SCHD screens for durable dividend payers, holds $112.3 billion in net assets and pays a trailing yield near 2.94%.
A pending IRS ruling, rising commodity costs, and more test whether the payouts of these passive income Dividend Kings can survive.
Benchmark PG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for The Procter & Gamble Company (PG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $171.72 | $399.87B | 25.79 | 3.26% | 18.23% | 29.42% | 2.46% | |
| $65.31 | $142.58B | 22.93 | -16.88% | — | — | 3.28% | |
| $108.15 | $35.9B | 10.93 | -14.17% | 19.93% | 151.82% | 4.61% | |
| $99.61 | $79.71B | 38.77 | 1.4% | 9.65% | 399.22% | 2.26% | |
| $112.48 | $26.65B | 34.65 | 1.57% | 12.41% | 18.21% | 1.05% | |
| $27.40 | $1.88B | 16.47 | -0.11% | 3.92% | 58.93% | 4.48% |
The Procter & Gamble Company (PG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
The Procter & Gamble Company (PG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 22, 2026·SEC
Oct 22, 2026·SEC
Oct 16, 2026·SEC
Get notified when PG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
The Procter & Gamble Company (PG) stock FAQ — growth, dividends, profitability & financials explained
The Procter & Gamble Company (PG) reported $87.92B in revenue over the trailing twelve months. Revenue was $87.03B in fiscal year 2026. That is 143% more than the $35.76B of fiscal year 1997.
The Procter & Gamble Company (PG) grew revenue by 3.5% over the trailing twelve months, compared with the twelve months before.
Yes. The Procter & Gamble Company (PG) earned $16.03B in net income over the trailing twelve months (a 18.2% net margin).
Yes. The Procter & Gamble Company (PG) pays a dividend that yields 2.46% at the current price, a moderate yield.
The Procter & Gamble Company (PG) had a return on equity (ROE) of 29.4% over the trailing twelve months. That is well above the market's typical 10-15%.
The Procter & Gamble Company (PG) generated $15.34B in free cash flow over the trailing twelve months.